ICON plc Releases Findings from Two Biotech Sector Survey
I'm PortAI, I can summarize articles.
ICON plc's surveys reveal global biotech trends, highlighting APAC's investment growth and China's positive impact. Funding challenges persist, with 41% seeking more R&D funds. VC funding is significant in APAC. Talent shortages are a concern, especially in APAC. Cell therapy leads pipelines, with neurology, cardiovascular, and immune disorders gaining focus. Drug development complexity is a major risk, but digital technologies like AI are expected to accelerate R&D. China's biotech challenges align globally, with less geopolitical concern and strong investment confidence.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments